For Immediate Release
Chicago, IL – June 13, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Exxon Mobil Corp.
XOM
, The Coca-Cola Co.
KO
, Thermo Fisher Scientific Inc.
TMO
, The Progressive Corp.
PGR
, and Dominion Energy, Inc.
D
.
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Exxon Mobil, Coca-Cola and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corp., The Coca-Cola Co., and Thermo Fisher Scientific Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can
see all of today’s research reports here >>>
Exxon Mobil
shares have outperformed the Zacks Oil and Gas – Integrated – International industry over the past year (+71.4% vs. +55.9%). The company’s bellwether status and an optimal integrated capital structure that has historically produced industry-leading returns make it a relatively lower-risk energy sector play.
The company made three oil discoveries in the Stabroek Block, which will increase its recoverable resources estimates to 11 billion oil-equivalent barrels. It also has a strong presence in the prolific Permian Basin, where it continues to lower its fracking & drilling costs.
To capitalize on mounting demand for clean energy, ExxonMobil is making efforts to create more efficient fuels while reducing emissions. Notably, it has significantly lower debt exposure than other integrated majors. ExxonMobil has increased its stock repurchase program from $10 billion to $30 billion. The energy giant has planned to execute the repurchases through next year.
(You can
read the full research report Exxom Mobil here >>>
)
Coca-Cola
shares have outperformed the Beverages – Soft drinks industry over the past year (+14.0% vs. +8.2%). The company benefited from the strategic transformation and ongoing recovery around the world. Strength across the majority of the markets, investments in the marketplace, recovery in certain markets as well as the cycling of last year’s pandemic-led impacts aided volumes.
The company retained its upbeat 2022 view. It is poised to gain from innovations and accelerating digital investments.
However, pressures from higher supply chain costs, including transportation and input costs remain. Higher marketing spending are also concerning. Also, the unfavorable currency is expected to hurt the top and bottom lines in the second quarter and 2022.
(You can
read the full research report Coca-Cola here >>>
)
Thermo Fisher
shares have outperformed the Medical – Instruments industry over the past year (+16.4% vs. -21.1%). The company’s robust year-over-year revenue growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.
The company’s strategic acquisitions of PPD, Inc. and PeproTech raise investors’ confidence. Thermo Fisher’s accelerated investments to expand bioproduction capacity also buoy optimism. The upbeat guidance for 2022 is indicative that this growth momentum will continue.
However, the year-over-year decline in revenues in the Specialty Diagnostics segment is disappointing. The contraction of both margins does not bode well either.
(You can
read the full research report Thermo Fisher here >>>
)
Other noteworthy reports we are featuring today include The Progressive Corp., and Dominion Energy, Inc.
Why Haven’t You Looked at Zacks’ Top Stocks?
Our 5 best-performing strategies have blown away the S&P’s impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%,
and
+95.3%
. Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report